1. Endometriosis can negatively impact ovarian reserve by damaging follicles through inflammation, fibrosis, and reduced vascularization caused by the disease itself or surgery to remove endometriotic cysts.
2. Anti-Mullerian hormone (AMH) levels tend to be lower in women with endometriosis, with more severe reductions seen with bilateral disease, larger cysts, more fibrosis, and longer disease duration.
3. When considering surgery or fertility treatments for endometriosis patients with low ovarian reserve, factors like the woman's age, infertility duration, pelvic pain levels, recurrence risk, and ovarian reserve markers must be evaluated individually to optimize outcomes while preserving future fertility potential.
This document discusses various factors that can optimize ART (assisted reproductive technology) outcomes. It addresses:
1) Patient selection criteria like age, BMI, lifestyle factors, medical and reproductive history that can impact success rates.
2) Techniques like using biomarkers to personalize ovarian stimulation protocols, recombinant hormones, antagonist protocols, and LH supplementation that can improve yield and outcomes.
3) Laboratory best practices for media, vitrification, embryo selection through PGS/morphological grading, and single embryo transfer that can maximize success while minimizing risks.
The document provides evidence-based guidance on optimizing each step of the ART process from patient screening to embryo transfer.
This document discusses evaluation and treatment of infertility for both male and female patients. It provides details on:
1. Evaluating both male and female partners simultaneously, including medical history, physical exam, and laboratory tests to detect underlying causes of infertility.
2. Common causes of male infertility like varicocele, infections, genetic issues, lifestyle factors etc. Evaluation includes semen analysis, hormone levels and identifying correctable issues.
3. Age is a major factor in female fertility, with risks increasing after age 35. Evaluation focuses on menstrual/obstetric history and detecting treatable conditions.
The goal is to allow natural conception if possible by addressing correctable issues, while assisted reproduction is an option if
Hysteroscopic surgery can effectively treat various intrauterine pathologies that cause infertility such as polyps, fibroids, adhesions, and septums. It allows for direct visualization and removal of abnormalities, improving chances for spontaneous or assisted conception. While hysteroscopy is considered the gold standard for diagnosing intrauterine issues, less invasive methods like ultrasound and HSG are usually sufficient. Routine hysteroscopy before first IVF is not recommended as it does not improve live birth rates, but may be beneficial after repeated failures. Operative hysteroscopy can significantly enhance fertility outcomes.
Predictive Factors influencing pregnancy rate after intrauterine inseminationDrRokeyaBegum
Intrauterine insemination (IUI) is an assisted reproduction procedure that involves the deposition of a processed semen sample in the upper uterine cavity.This is non invasive and cost effective first line therapy for infertile couple.IUI can be done easily in simple setups.
The Role of laparoscopy in the era of ARTDrRokeyaBegum
The advancement of new perspectives in assisted reproductive technology (ART) through the use of modern infertility evaluation technique Stillclinician needs to reassess how infertility should be best treated.
Recently the focus of treatment for infertility has shifted from systematic correction of each identified factor.
This document discusses the management of uterine fibroids. It defines fibroids as benign tumors of the myometrium. Symptoms vary and include menstrual problems, pressure symptoms, and reproductive dysfunction like infertility. Diagnosis involves imaging like ultrasound and MRI. Treatment options include expectant management for asymptomatic cases, medical treatment to relieve symptoms using drugs like progesterone or GnRH analogues, and surgical options like hysterectomy or myomectomy. Factors in surgical decision making include size and location of fibroids, desire for future fertility, and expertise of the surgeon. Myomectomy aims to preserve the uterus but carries risks of recurrence and complications in future pregnancies.
Challenges - In management of infertilityDrRokeyaBegum
Over fertility is a problem of Bangladesh.Still infertility is an issue 1 in 7 couples have difficulties to conceive.
Inability to create a desired pregnancy that culminates in the Birth of child is likely to create a life crisis for women and their partners.
This document discusses various factors that can optimize ART (assisted reproductive technology) outcomes. It addresses:
1) Patient selection criteria like age, BMI, lifestyle factors, medical and reproductive history that can impact success rates.
2) Techniques like using biomarkers to personalize ovarian stimulation protocols, recombinant hormones, antagonist protocols, and LH supplementation that can improve yield and outcomes.
3) Laboratory best practices for media, vitrification, embryo selection through PGS/morphological grading, and single embryo transfer that can maximize success while minimizing risks.
The document provides evidence-based guidance on optimizing each step of the ART process from patient screening to embryo transfer.
This document discusses evaluation and treatment of infertility for both male and female patients. It provides details on:
1. Evaluating both male and female partners simultaneously, including medical history, physical exam, and laboratory tests to detect underlying causes of infertility.
2. Common causes of male infertility like varicocele, infections, genetic issues, lifestyle factors etc. Evaluation includes semen analysis, hormone levels and identifying correctable issues.
3. Age is a major factor in female fertility, with risks increasing after age 35. Evaluation focuses on menstrual/obstetric history and detecting treatable conditions.
The goal is to allow natural conception if possible by addressing correctable issues, while assisted reproduction is an option if
Hysteroscopic surgery can effectively treat various intrauterine pathologies that cause infertility such as polyps, fibroids, adhesions, and septums. It allows for direct visualization and removal of abnormalities, improving chances for spontaneous or assisted conception. While hysteroscopy is considered the gold standard for diagnosing intrauterine issues, less invasive methods like ultrasound and HSG are usually sufficient. Routine hysteroscopy before first IVF is not recommended as it does not improve live birth rates, but may be beneficial after repeated failures. Operative hysteroscopy can significantly enhance fertility outcomes.
Predictive Factors influencing pregnancy rate after intrauterine inseminationDrRokeyaBegum
Intrauterine insemination (IUI) is an assisted reproduction procedure that involves the deposition of a processed semen sample in the upper uterine cavity.This is non invasive and cost effective first line therapy for infertile couple.IUI can be done easily in simple setups.
The Role of laparoscopy in the era of ARTDrRokeyaBegum
The advancement of new perspectives in assisted reproductive technology (ART) through the use of modern infertility evaluation technique Stillclinician needs to reassess how infertility should be best treated.
Recently the focus of treatment for infertility has shifted from systematic correction of each identified factor.
This document discusses the management of uterine fibroids. It defines fibroids as benign tumors of the myometrium. Symptoms vary and include menstrual problems, pressure symptoms, and reproductive dysfunction like infertility. Diagnosis involves imaging like ultrasound and MRI. Treatment options include expectant management for asymptomatic cases, medical treatment to relieve symptoms using drugs like progesterone or GnRH analogues, and surgical options like hysterectomy or myomectomy. Factors in surgical decision making include size and location of fibroids, desire for future fertility, and expertise of the surgeon. Myomectomy aims to preserve the uterus but carries risks of recurrence and complications in future pregnancies.
Challenges - In management of infertilityDrRokeyaBegum
Over fertility is a problem of Bangladesh.Still infertility is an issue 1 in 7 couples have difficulties to conceive.
Inability to create a desired pregnancy that culminates in the Birth of child is likely to create a life crisis for women and their partners.
This document discusses recurrent pregnancy loss and provides guidelines for evaluation and management. It defines recurrent pregnancy loss as three or more consecutive spontaneous losses before 20 weeks gestation. The main causes discussed include genetic factors, immunological factors like antiphospholipid syndrome, anatomical uterine anomalies, infections, endocrine disorders like diabetes and thyroid disease, and hematological disorders. A thorough evaluation is recommended, including history, examination, testing for genetic and hematological abnormalities. Current treatment approaches discussed include surgical correction of uterine anomalies, anticoagulation for antiphospholipid syndrome, tight glycemic control for diabetes, and immunotherapy. The success rate after evaluation and treatment is improved compared to without intervention.
Placenta Accreta Spectrum Disorders Challenges and managementAhmed Elbohoty
This document discusses placenta accreta spectrum disorders, including challenges in management. Key points include: PAS disorders occur when the placenta invades the uterine wall abnormally. Risk factors include prior c-sections and placenta previa. Incidence has risen with increasing c-section rates. Ultrasound is used to diagnose but risks false positives/negatives. Management involves a multidisciplinary team and individualized delivery timing/plan. Surgery poses challenges like hemorrhage, but techniques like leaving the placenta in situ and internal iliac ligation can help. Careful dissection is needed to avoid injury to structures like the bladder and ureters.
May occur very early on during the attachment or migration stages (No objective evidence e.g. –ve hCG)
May also occur at a later stage (+ve hCG) but process becomes disrupted
Definition: Refers to the failure of the embryo to reach a stage when an intrauterine gestational sac is recognized by ultrasonography.
Implantation failure can apply to patients undergoing ART and patients trying to conceive without any fertility treatment.
It is a separate entity from RPL
Orvieto et al - 3 failed IVF-ET cycles with good quality embryos transferred .
Zeyneloglu et al. - 3 unsuccessful IVF specifically with two embryos of high quality
Simon and Laufer - embryo & endometrium can both play an active role in RIF
Coughlan et al. suggest a more complete working definition taking into account maternal age, number of embryos transferred, and number of cycles completed.
They define RIF as the failure of clinical pregnancy after 4 good quality embryo transfers, with at least three fresh or frozen IVF cycles, and in women under the age of 40
RIF is a complex problem with a wide variety of etiologies / mechanisms/ treatment options.
Recommendations vary depending on the source of their problem. Perhaps the best and yet most complex answer is personalized medicine, a personal approach to each patient depending on her unique set of characteristics.
It would help to establish a set of standardized tests to use, in order to do a preliminary evaluation on each patient, which would then hopefully direct the approach of treatment for each individual couple.
This can be implemented when we have well designed studies that will help us to establish new protocols.
This document summarizes evidence-based guidelines for preparing patients for ICSI (intracytoplasmic sperm injection). It discusses evaluating patients' ovarian reserve, investigating uterine cavities, assessing endometrial receptivity, screening for infections, and optimizing lifestyle factors like smoking, alcohol, and weight. Key recommendations include testing ovarian reserve with day 3 FSH and estradiol levels and antral follicle counts, treating any uterine abnormalities found on hysteroscopy or ultrasound, and advising patients to quit smoking and limit alcohol and caffeine intake to improve ICSI success rates.
This document discusses fertility preservation techniques. It begins by defining ovarian reserve and discussing age-related declines in fertility. It describes medical indications for fertility preservation in cancer patients, including for both pre-pubertal and post-pubertal individuals. For pre-pubertal patients, options include ovarian tissue cryopreservation while for post-pubertal patients options are oocyte and embryo cryopreservation. The document also discusses the use of GnRH analogs to protect ovarian reserve during cancer treatment and debates the ethics of fertility preservation for social reasons like career planning. It concludes by looking to future techniques like in vitro maturation of oocytes.
Recurrent pregnancy loss is defined as the loss of three or more consecutive pregnancies. It can be caused by anatomical, genetic, infectious, immune, or other factors. Common anatomical causes include uterine abnormalities like septate uterus and fibroids. Genetic factors may include chromosomal abnormalities in the products of conception or balanced translocations in one or both parents. Infectious causes like bacterial vaginosis can also contribute. The immune condition antiphospholipid antibody syndrome, characterized by antibodies that cause blood clots, increases the risk of recurrent loss. Treatment depends on the underlying cause but may include surgery to correct uterine anomalies, antibiotics for infections, low-dose aspirin with or without heparin for antiphospholip
This document discusses recurrent pregnancy loss. It defines recurrent miscarriage as three or more consecutive spontaneous abortions before 20 weeks of gestation. Evaluation and treatment should focus on common and treatable causes like uterine anomalies, endocrine abnormalities, autoimmune disorders, thrombophilia, and genetic factors. Management may include surgical correction of septate uterus, treatment of thyroid disorders, anticoagulation for antiphospholipid syndrome, and assisted reproductive technology for translocations. Unexplained recurrent loss can be managed with lifestyle changes, progesterone, low-dose aspirin, and close monitoring during subsequent pregnancies.
- Recurrent pregnancy loss is defined as 3 or more consecutive miscarriages before 20 weeks.
- Genetic causes like chromosomal abnormalities are a major cause and account for around 70% of early miscarriages. Karyotyping of pregnancy tissue can identify chromosomal abnormalities.
- Advanced parental age increases the risk of genetic defects leading to miscarriage due to declining egg/sperm quality. Parental karyotyping may identify balanced translocations in 3-5% of couples.
- A thorough evaluation including genetic, endocrine, anatomical, immunological, and infectious factors can identify a cause in 60% of recurrent pregnancy loss cases.
This document discusses recurrent pregnancy loss and provides information on definitions, incidence, causes, investigations, and guidelines. Some key points:
- Recurrent pregnancy loss is defined as 3 or more clinically recognized pregnancy losses before 20 weeks. The incidence is about 1 in 300 pregnancies.
- Common causes include genetic factors in the parents or embryo, anatomic abnormalities, endocrine/immune/infectious factors, and inherited thrombophilias.
- Investigations should include parental karyotyping after 2 losses, and karyotyping of pregnancy tissues is recommended by RCOG guidelines to provide counseling and predict outcomes of future pregnancies.
- Biomarkers and ultrasound can provide information on predicting outcomes,
Recurrent miscarriage is defined as 3 or more consecutive spontaneous pregnancy losses under 20 weeks gestation. It affects 1% of women and can be caused by many potential genetic, anatomical, hormonal, and immunological factors. Evaluation involves testing the parents' chromosomes through karyotyping of their blood, testing the chromosomes of miscarried fetal tissue when possible, and examining the uterus and fallopian tubes through ultrasound, hysterosalpingogram, hysteroscopy, or laparoscopy to check for anatomical abnormalities. Finding the cause helps guide treatment such as surgery to remove uterine anomalies which may improve future pregnancy outcomes.
Systemic lupus erythematosus during pregnancyDrRokeyaBegum
This document discusses systemic lupus erythematosus (SLE) during pregnancy. It describes SLE as an autoimmune disease characterized by autoantibodies that can affect multiple organs. Pregnancy can trigger disease flares in SLE patients. The document outlines criteria for SLE diagnosis, potential adverse effects of SLE on pregnancy like abortion and preeclampsia, recommended monitoring and treatment during pregnancy including immunosuppressants, and risks for conditions in offspring like congenital heart block. Good outcomes are associated with disease remission prior to conception and treatment including hydroxychloroquine use during pregnancy.
recurrent miscarriage is a real clinical problem with different aetioogies. However, recent observations pointed to vascular dysfunction as a main underlying factor: how ? this talk may help in illustrating this
This document provides guidelines for evaluating and treating infertility in couples. It recommends investigating couples after 6 months to 1 year of unsuccessful conception depending on the woman's age. Common causes of infertility include male factors (30%), female factors (45%), and unexplained causes (25%). Recommended initial investigations include semen analysis, HSG, and midluteal progesterone levels. The document provides treatment guidelines for various causes of infertility including PCOS, ovarian dysfunction, uterine fibroids, uterine anomalies, and more. It recommends treatments such as clomiphene, metformin, myomectomy, hysteroscopic surgery, IVF, and others depending on the diagnosis.
This document discusses complications that can arise during ART (assisted reproductive technology) and pregnancies resulting from ART. It describes common complications at different stages of ART like ovarian hyperstimulation syndrome, ectopic pregnancies, miscarriages, preterm births and multiple pregnancies. It also discusses risks of maternal conditions like preeclampsia and gestational diabetes. Further, it outlines fetal risks such as molar pregnancies, low birth weight, prematurity from multiple pregnancies and increased risks of congenital abnormalities. The document provides recommendations to help prevent complications and improve ART outcomes.
This document discusses various aspects of assisted reproductive technology (ART) including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). It provides information on the causes of infertility, procedures for IVF such as egg retrieval, embryo transfer, and blastocyst culture. The document also discusses who may benefit from IVF and ICSI, including those with male factor infertility issues or previous IVF failures. Other ART procedures mentioned include zygote intrafallopian transfer, gamete intrafallopian transfer, and potential future techniques like creating artificial gametes.
the objective is to clarify the problem of recurrent implantation failure , regarding the definition, the caused, diagnosis, and management in cases of IVF
Dr. Laxmi Shrikhande has had an illustrious career in obstetrics and gynecology. She has held numerous leadership positions including Chairperson for ICOG, national corresponding editor, and founder and president of various medical organizations. She has received several awards for her contributions to women's health. Her career highlights include over 450 guest lectures, 31 national publications, and sensitizing over 200,000 adolescents on health issues. She currently serves as the medical director of Shrikhande Fertility Clinic in Nagpur, Maharashtra.
This document lists the professional qualifications and positions held by Dr. Laxmi Shrikhande, including Chairperson for various medical committees, publications, awards received, and presentations given. It then provides an overview of her upcoming presentation on Perimenopausal Bleeding, covering definitions, classifications, evaluation, treatment options for structural and non-structural causes, and specific treatment approaches like hormonal therapy, NSAIDs, and levonorgestrel intrauterine devices.
This document discusses evidence-based infertility treatment and includes the following key points:
- It introduces evidence-based medicine (EBM) and describes how clinical practice is transitioning from experience-oriented to evidence-based.
- It provides examples of models for creating medical evidence, including randomized controlled trials (RCTs) and systematic reviews. An RCT studying a novel gonadotropin protocol is summarized.
- Economic evaluations are discussed as a model, using Markov modeling to compare costs and outcomes of fertility drug options.
- The concept of prognosis modeling to estimate natural conception chances and IVF success is explained.
- In closing, it briefly touches on other topics like using cabergoline
Endometriosis can occasionally present in postmenopausal women, though it is rare, occurring in 2-5% of cases. It is usually a continuation of preexisting endometriosis but can also arise de novo. Estrogen, especially estrone, can continue to stimulate residual endometriotic lesions after menopause. Diagnosis is via laparoscopy and histological confirmation. Treatment involves surgery to remove lesions followed by medical management with aromatase inhibitors or progestogens if needed. Hormone therapy for menopausal symptoms carries a risk of stimulating residual endometriosis and needs to be carefully managed.
This document discusses endometriosis in menopause. Some key points:
1. Endometriosis is an estrogen-dependent condition that typically presents during reproductive years but can occasionally present during or after menopause, either as continuation of existing disease or new lesions.
2. After menopause, loss of estrogen through natural or induced menopause usually leads to regression of endometriotic lesions and pain relief.
3. Rarely, endometriosis can develop de novo after menopause, related to extra-ovarian estrogen from various sources like adipose tissue or medication.
4. Diagnosis of post-menopausal endometriosis requires lapar
This document discusses recurrent pregnancy loss and provides guidelines for evaluation and management. It defines recurrent pregnancy loss as three or more consecutive spontaneous losses before 20 weeks gestation. The main causes discussed include genetic factors, immunological factors like antiphospholipid syndrome, anatomical uterine anomalies, infections, endocrine disorders like diabetes and thyroid disease, and hematological disorders. A thorough evaluation is recommended, including history, examination, testing for genetic and hematological abnormalities. Current treatment approaches discussed include surgical correction of uterine anomalies, anticoagulation for antiphospholipid syndrome, tight glycemic control for diabetes, and immunotherapy. The success rate after evaluation and treatment is improved compared to without intervention.
Placenta Accreta Spectrum Disorders Challenges and managementAhmed Elbohoty
This document discusses placenta accreta spectrum disorders, including challenges in management. Key points include: PAS disorders occur when the placenta invades the uterine wall abnormally. Risk factors include prior c-sections and placenta previa. Incidence has risen with increasing c-section rates. Ultrasound is used to diagnose but risks false positives/negatives. Management involves a multidisciplinary team and individualized delivery timing/plan. Surgery poses challenges like hemorrhage, but techniques like leaving the placenta in situ and internal iliac ligation can help. Careful dissection is needed to avoid injury to structures like the bladder and ureters.
May occur very early on during the attachment or migration stages (No objective evidence e.g. –ve hCG)
May also occur at a later stage (+ve hCG) but process becomes disrupted
Definition: Refers to the failure of the embryo to reach a stage when an intrauterine gestational sac is recognized by ultrasonography.
Implantation failure can apply to patients undergoing ART and patients trying to conceive without any fertility treatment.
It is a separate entity from RPL
Orvieto et al - 3 failed IVF-ET cycles with good quality embryos transferred .
Zeyneloglu et al. - 3 unsuccessful IVF specifically with two embryos of high quality
Simon and Laufer - embryo & endometrium can both play an active role in RIF
Coughlan et al. suggest a more complete working definition taking into account maternal age, number of embryos transferred, and number of cycles completed.
They define RIF as the failure of clinical pregnancy after 4 good quality embryo transfers, with at least three fresh or frozen IVF cycles, and in women under the age of 40
RIF is a complex problem with a wide variety of etiologies / mechanisms/ treatment options.
Recommendations vary depending on the source of their problem. Perhaps the best and yet most complex answer is personalized medicine, a personal approach to each patient depending on her unique set of characteristics.
It would help to establish a set of standardized tests to use, in order to do a preliminary evaluation on each patient, which would then hopefully direct the approach of treatment for each individual couple.
This can be implemented when we have well designed studies that will help us to establish new protocols.
This document summarizes evidence-based guidelines for preparing patients for ICSI (intracytoplasmic sperm injection). It discusses evaluating patients' ovarian reserve, investigating uterine cavities, assessing endometrial receptivity, screening for infections, and optimizing lifestyle factors like smoking, alcohol, and weight. Key recommendations include testing ovarian reserve with day 3 FSH and estradiol levels and antral follicle counts, treating any uterine abnormalities found on hysteroscopy or ultrasound, and advising patients to quit smoking and limit alcohol and caffeine intake to improve ICSI success rates.
This document discusses fertility preservation techniques. It begins by defining ovarian reserve and discussing age-related declines in fertility. It describes medical indications for fertility preservation in cancer patients, including for both pre-pubertal and post-pubertal individuals. For pre-pubertal patients, options include ovarian tissue cryopreservation while for post-pubertal patients options are oocyte and embryo cryopreservation. The document also discusses the use of GnRH analogs to protect ovarian reserve during cancer treatment and debates the ethics of fertility preservation for social reasons like career planning. It concludes by looking to future techniques like in vitro maturation of oocytes.
Recurrent pregnancy loss is defined as the loss of three or more consecutive pregnancies. It can be caused by anatomical, genetic, infectious, immune, or other factors. Common anatomical causes include uterine abnormalities like septate uterus and fibroids. Genetic factors may include chromosomal abnormalities in the products of conception or balanced translocations in one or both parents. Infectious causes like bacterial vaginosis can also contribute. The immune condition antiphospholipid antibody syndrome, characterized by antibodies that cause blood clots, increases the risk of recurrent loss. Treatment depends on the underlying cause but may include surgery to correct uterine anomalies, antibiotics for infections, low-dose aspirin with or without heparin for antiphospholip
This document discusses recurrent pregnancy loss. It defines recurrent miscarriage as three or more consecutive spontaneous abortions before 20 weeks of gestation. Evaluation and treatment should focus on common and treatable causes like uterine anomalies, endocrine abnormalities, autoimmune disorders, thrombophilia, and genetic factors. Management may include surgical correction of septate uterus, treatment of thyroid disorders, anticoagulation for antiphospholipid syndrome, and assisted reproductive technology for translocations. Unexplained recurrent loss can be managed with lifestyle changes, progesterone, low-dose aspirin, and close monitoring during subsequent pregnancies.
- Recurrent pregnancy loss is defined as 3 or more consecutive miscarriages before 20 weeks.
- Genetic causes like chromosomal abnormalities are a major cause and account for around 70% of early miscarriages. Karyotyping of pregnancy tissue can identify chromosomal abnormalities.
- Advanced parental age increases the risk of genetic defects leading to miscarriage due to declining egg/sperm quality. Parental karyotyping may identify balanced translocations in 3-5% of couples.
- A thorough evaluation including genetic, endocrine, anatomical, immunological, and infectious factors can identify a cause in 60% of recurrent pregnancy loss cases.
This document discusses recurrent pregnancy loss and provides information on definitions, incidence, causes, investigations, and guidelines. Some key points:
- Recurrent pregnancy loss is defined as 3 or more clinically recognized pregnancy losses before 20 weeks. The incidence is about 1 in 300 pregnancies.
- Common causes include genetic factors in the parents or embryo, anatomic abnormalities, endocrine/immune/infectious factors, and inherited thrombophilias.
- Investigations should include parental karyotyping after 2 losses, and karyotyping of pregnancy tissues is recommended by RCOG guidelines to provide counseling and predict outcomes of future pregnancies.
- Biomarkers and ultrasound can provide information on predicting outcomes,
Recurrent miscarriage is defined as 3 or more consecutive spontaneous pregnancy losses under 20 weeks gestation. It affects 1% of women and can be caused by many potential genetic, anatomical, hormonal, and immunological factors. Evaluation involves testing the parents' chromosomes through karyotyping of their blood, testing the chromosomes of miscarried fetal tissue when possible, and examining the uterus and fallopian tubes through ultrasound, hysterosalpingogram, hysteroscopy, or laparoscopy to check for anatomical abnormalities. Finding the cause helps guide treatment such as surgery to remove uterine anomalies which may improve future pregnancy outcomes.
Systemic lupus erythematosus during pregnancyDrRokeyaBegum
This document discusses systemic lupus erythematosus (SLE) during pregnancy. It describes SLE as an autoimmune disease characterized by autoantibodies that can affect multiple organs. Pregnancy can trigger disease flares in SLE patients. The document outlines criteria for SLE diagnosis, potential adverse effects of SLE on pregnancy like abortion and preeclampsia, recommended monitoring and treatment during pregnancy including immunosuppressants, and risks for conditions in offspring like congenital heart block. Good outcomes are associated with disease remission prior to conception and treatment including hydroxychloroquine use during pregnancy.
recurrent miscarriage is a real clinical problem with different aetioogies. However, recent observations pointed to vascular dysfunction as a main underlying factor: how ? this talk may help in illustrating this
This document provides guidelines for evaluating and treating infertility in couples. It recommends investigating couples after 6 months to 1 year of unsuccessful conception depending on the woman's age. Common causes of infertility include male factors (30%), female factors (45%), and unexplained causes (25%). Recommended initial investigations include semen analysis, HSG, and midluteal progesterone levels. The document provides treatment guidelines for various causes of infertility including PCOS, ovarian dysfunction, uterine fibroids, uterine anomalies, and more. It recommends treatments such as clomiphene, metformin, myomectomy, hysteroscopic surgery, IVF, and others depending on the diagnosis.
This document discusses complications that can arise during ART (assisted reproductive technology) and pregnancies resulting from ART. It describes common complications at different stages of ART like ovarian hyperstimulation syndrome, ectopic pregnancies, miscarriages, preterm births and multiple pregnancies. It also discusses risks of maternal conditions like preeclampsia and gestational diabetes. Further, it outlines fetal risks such as molar pregnancies, low birth weight, prematurity from multiple pregnancies and increased risks of congenital abnormalities. The document provides recommendations to help prevent complications and improve ART outcomes.
This document discusses various aspects of assisted reproductive technology (ART) including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). It provides information on the causes of infertility, procedures for IVF such as egg retrieval, embryo transfer, and blastocyst culture. The document also discusses who may benefit from IVF and ICSI, including those with male factor infertility issues or previous IVF failures. Other ART procedures mentioned include zygote intrafallopian transfer, gamete intrafallopian transfer, and potential future techniques like creating artificial gametes.
the objective is to clarify the problem of recurrent implantation failure , regarding the definition, the caused, diagnosis, and management in cases of IVF
Dr. Laxmi Shrikhande has had an illustrious career in obstetrics and gynecology. She has held numerous leadership positions including Chairperson for ICOG, national corresponding editor, and founder and president of various medical organizations. She has received several awards for her contributions to women's health. Her career highlights include over 450 guest lectures, 31 national publications, and sensitizing over 200,000 adolescents on health issues. She currently serves as the medical director of Shrikhande Fertility Clinic in Nagpur, Maharashtra.
This document lists the professional qualifications and positions held by Dr. Laxmi Shrikhande, including Chairperson for various medical committees, publications, awards received, and presentations given. It then provides an overview of her upcoming presentation on Perimenopausal Bleeding, covering definitions, classifications, evaluation, treatment options for structural and non-structural causes, and specific treatment approaches like hormonal therapy, NSAIDs, and levonorgestrel intrauterine devices.
This document discusses evidence-based infertility treatment and includes the following key points:
- It introduces evidence-based medicine (EBM) and describes how clinical practice is transitioning from experience-oriented to evidence-based.
- It provides examples of models for creating medical evidence, including randomized controlled trials (RCTs) and systematic reviews. An RCT studying a novel gonadotropin protocol is summarized.
- Economic evaluations are discussed as a model, using Markov modeling to compare costs and outcomes of fertility drug options.
- The concept of prognosis modeling to estimate natural conception chances and IVF success is explained.
- In closing, it briefly touches on other topics like using cabergoline
Endometriosis can occasionally present in postmenopausal women, though it is rare, occurring in 2-5% of cases. It is usually a continuation of preexisting endometriosis but can also arise de novo. Estrogen, especially estrone, can continue to stimulate residual endometriotic lesions after menopause. Diagnosis is via laparoscopy and histological confirmation. Treatment involves surgery to remove lesions followed by medical management with aromatase inhibitors or progestogens if needed. Hormone therapy for menopausal symptoms carries a risk of stimulating residual endometriosis and needs to be carefully managed.
This document discusses endometriosis in menopause. Some key points:
1. Endometriosis is an estrogen-dependent condition that typically presents during reproductive years but can occasionally present during or after menopause, either as continuation of existing disease or new lesions.
2. After menopause, loss of estrogen through natural or induced menopause usually leads to regression of endometriotic lesions and pain relief.
3. Rarely, endometriosis can develop de novo after menopause, related to extra-ovarian estrogen from various sources like adipose tissue or medication.
4. Diagnosis of post-menopausal endometriosis requires lapar
This document discusses menopause and endometriosis. Some key points:
1. Endometriosis is an estrogen-dependent condition that typically presents during reproductive years but can occasionally present during or after menopause.
2. At menopause, decreased estrogen levels usually lead to regression of endometriotic lesions and reduced pain.
3. Post-menopausal endometriosis is dependent on extra-ovarian estrogen sources and can occur as persistence of pre-existing disease or develop de novo.
4. Diagnosis requires laparoscopy and histological confirmation of endometriotic lesions. Imaging like ultrasound and MRI can help identify locations like ovarian cysts.
This document discusses endometriosis in menopause and post-menopause. It notes that while endometriosis is typically an estrogen-dependent condition that affects women during their reproductive years, it can occasionally present during or after menopause. After menopause, low estrogen levels normally lead to regression of endometriotic lesions. However, extra-ovarian sources of estrogen can still fuel endometriosis. Diagnosis is usually via laparoscopy and histological confirmation. Treatment may involve surgery, aromatase inhibitors, or progestogens to reduce estrogen levels and related symptoms. Managing menopausal symptoms in women with a history of endometriosis requires special consideration to balance relief of symptoms with
Future Directions in Endometriosis Management 11.04.2021.pptxKawita Bapat
Dr. Kawita Bapat's document discusses future directions in endometriosis management. It provides an overview of endometriosis, including sites of occurrence, symptoms, diagnosis, and current treatment approaches. The document also discusses newer treatment options such as elagolix, ulipristal, and resveratrol. Finally, it outlines criteria for an ideal future medication to treat endometriosis, including being curative rather than suppressive and having an acceptable side effect profile.
An ectopic pregnancy occurs when the fertilized egg attaches itself in a place other than inside the uterus.
Fibroids, also known as uterine myomas, leiomyomas, or fibromas, are firm, compact tumors that are made of smooth muscle cells and fibrous connective tissue that develop in the uterus.
It is the benign kind of Gestational Trophoblastic Disease (GTD) while the cancerous kind is Invasive mole, Epithelioid trophoblastic tumor, Choriocarcinoma and Placental Site Tumor. H. Mole could lead to Invasive moles or Choriocarcinoma if not treated immediately with prophylactic chemotherapy.
Uterine fibroids are benign tumors that develop in the uterus. They affect around 20-80% of women by age 50 and are more common in African American women. The three main types are intramural, subserosal, and submucosal fibroids. Symptoms include heavy bleeding, pelvic pain, pressure symptoms, and infertility. Treatment options include medical management with drugs to shrink fibroids, surgical removal via myomectomy or hysterectomy, or minimally invasive procedures like uterine artery embolization or ablation. Complications can include degeneration, infection, and rarely sarcoma. Nursing care focuses on managing pain, preventing infection, addressing bowel issues, and supporting emotional adjustment to changes in fertility status
When more is not better: The 10 ‘Don’ts’ in Endometriosis ManagementAhmed Al Amely
This document outlines 10 recommendations ("don'ts") for the management of endometriosis:
1) Do not suggest laparoscopy for superficial peritoneal endometriosis in infertile women without pain symptoms.
2) Do not recommend controlled ovarian stimulation and IUI for endometriosis-related infertility at any stage.
3) Do not remove small ovarian endometriomas solely to improve IVF success in infertile patients.
4) Do not remove uncomplicated deep lesions in asymptomatic women or those where medical treatment is effective.
5) Do not systematically request additional diagnostic tests for known non-subocclusive colorectal endometriosis responding to treatment.
This document provides information on endometriosis including:
- Endometriosis is a condition where tissue similar to the uterine lining grows outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum.
- Stages of endometriosis range from minimal to severe based on the extent of growth and severity of symptoms. Symptoms include pelvic pain and infertility.
- Risk factors include family history, early menarche, and nulliparity. Evaluation involves obtaining a detailed health history and performing a pelvic examination.
This document provides information on endometriosis including:
- Endometriosis is a condition where tissue similar to the uterine lining grows outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum.
- Stages of endometriosis range from minimal to severe based on the extent of growth and severity of symptoms. Symptoms include pelvic pain and infertility.
- Risk factors include family history, early menarche, and nulliparity. Evaluation involves obtaining a detailed health history and performing a pelvic examination.
This document provides information on endometriosis including:
- Definition, incidence, stages, and common sites of endometriosis implants. The most common sites are the ovaries, posterior and anterior cul-de-sac.
- Theories on the pathophysiology of endometriosis including retrograde menstruation, coelomic metaplasia, oxidative stress and inflammation, immune dysfunction, stem cells, and altered endometrial cell fate.
- Risk factors which increase likelihood of developing endometriosis include family history, nulliparity, early menarche, hormones, obesity, and uterine retroversion.
- Key aspects of evaluating a patient with endometriosis including
This document discusses endometriosis and its relationship to infertility. It covers several key points:
1. Endometriosis has three main types - peritoneal, ovarian, and rectovaginal - which are different entities.
2. Endometriosis can result in infertility through mechanical effects, endocrine abnormalities, changes to peritoneal fluid, immune system issues, and defects in oocytes.
3. Diagnosis is confirmed through laparoscopy, and mild or minimal endometriosis associated with infertility can be treated through laparoscopic destruction, expectant management, or GnRH agonists. Surgery aims to decrease inflammation and toxicity.
4. For endometriomas,
gyanaecology.endometriosis and adenomyosis.(dr.salama)student
The document summarizes endometriosis and adenomyosis. Endometriosis occurs when endometrial tissue grows outside the uterus, most commonly on the ovaries, uterine ligaments and pelvis. It causes pain and infertility. Adenomyosis involves endometrial tissue in the uterine wall. Both can be diagnosed by laparoscopy and treated through drugs or surgery, with hysterectomy providing definitive treatment for severe adenomyosis.
Endometriosis is a condition where endometrial tissue grows outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum. It causes pain and infertility and is most common during reproductive years. Theories for its cause include retrograde menstruation and genetic/immunological factors. Diagnosis involves symptoms, exam, laparoscopy, and imaging. Treatment options include pain medications, hormonal therapy like combined oral contraceptives or GnRH agonists, and surgery to remove lesions. While not curable, treatment aims to control pain and improve fertility.
A leiomyoma is a benign smooth muscle tumor that originates in the uterus. They are very common, affecting 20-40% of women during their reproductive years. The most common symptoms are abnormal uterine bleeding, pelvic pressure or pain. Treatment options include observation, medication/hormonal therapy, myomectomy (surgical removal), or hysterectomy depending on the severity of symptoms, size and location of fibroids, and desire for future fertility. Laparoscopic and vaginal approaches for myomectomy have benefits of less pain and faster recovery compared to open abdominal myomectomy.
Endometriosis is a condition where endometrial tissue grows outside the uterus, often resulting in pelvic pain and infertility. Key points:
- It is most common in women of reproductive age and is characterized by dysfunctional uterine tissue implants in the pelvis that cause pain, especially during periods.
- Diagnosis requires laparoscopy to visualize the implants. Treatment depends on severity and reproductive plans, and may include expectant care, hormonal therapies like oral contraceptives to induce pseudopregnancy, or surgery to remove implants and adhesions.
- Hormonal therapies aim to suppress menstruation and the ectopic endometrial tissue through continuous combination estrogen-progestin pills,
Adenomyosis, is a defined mass of cells within the uterine wall, is characterized as ectopic endometrial tissue within the myometrium in the uterus.
In adenomyosis, a series of immune responses is activated, including changes in both cellular and humoral immunity.
To know related details refer doctors answer --> https://www.icliniq.com/qa/adenomyosis/can-i-conceive-with-adenomyosis
This document discusses the management of infertility in women with endometriosis. It covers topics such as the relationship between endometriosis and infertility, guidelines for treatment, the pathophysiology of endometriosis-related infertility, diagnosing endometriosis, medical and surgical treatment options, assisted reproduction techniques for endometriosis patients, and specific considerations for deep endometriosis, endometriomas, and unexplained infertility. Treatment aims to relieve symptoms, remove or destroy endometrial lesions, and potentially improve fertility outcomes through methods like laparoscopic surgery, hormonal therapies, IUI, and IVF. However, the evidence on most effective approaches is still limited.
The document discusses damage control surgery (DCS) for postpartum hemorrhage (PPH). It provides:
1. DCS involves performing limited surgical interventions to control life-threatening bleeding and stabilizing the patient, then delaying definitive surgery until intensive care unit stabilization is achieved.
2. Indications for DCS include persistent bleeding, massive transfusion, hemodynamic instability, and the development of coagulopathy.
3. The key principles of DCS are rapid hemorrhage control, usually via packing, followed by resuscitation and correction of coagulopathy in the ICU before performing definitive surgery 48-72 hours later.
Controversy and consensus regarding management of recurrent pregnancy loss.pptxDrRokeyaBegum
This document discusses controversy and consensus regarding management of recurrent pregnancy loss. It provides definitions of miscarriage and recurrent pregnancy loss. It examines various potential causes of recurrent pregnancy loss including genetic, immunological, endocrine, anatomical, infectious, and male factors. For each factor, it discusses recommendations for investigation and management based on guidelines from various organizations. The document emphasizes taking a thorough history and investigating multiple potential causes through tests and scans to determine a tailored treatment plan aiming to prevent future miscarriages.
1. Caesarean myomectomy was historically discouraged due to risks of hemorrhage, difficulty securing hemostasis, and potential need for hysterectomy or blood transfusion.
2. However, recent evidence suggests that caesarean myomectomy can be safely performed by an experienced surgeon, even in cases of large myomas, without increasing intra- or post-operative complications when proper techniques are used.
3. Future fertility and subsequent pregnancy outcomes appear unaffected by caesarean myomectomy according to current evidence.
This document summarizes the repair of vesicovaginal fistulas (VVF) performed at Chittagong Medical College from 2001-2015. It discusses that VVF most often occurs due to prolonged obstructed labor causing tissue damage. The majority of VVF cases (94%) can be treated with vaginal repair using a Martius flap with a success rate of 94% and minor complications. While stress incontinence remains an issue, repeated attempts at repair can achieve success. The document recommends that dedicated gynecologists can perform VVF repair in Bangladesh using basic techniques and postoperative care to restore dignity to women suffering from this condition.
This document discusses myomectomy, which is a common surgery to remove uterine fibroids while preserving the uterus. It describes the different surgical approaches including open, endoscopic, hysteroscopic, and laparoscopic. For each approach, it provides details on patient selection, preoperative mapping and imaging, surgical tools and techniques, tips to prevent complications, and post-operative concerns. It emphasizes the importance of adequate training to equip gynecologists with the skills to perform these minimally invasive procedures.
Diagnosis of PCOS MCMCTACONSESSION4.pptxDrRokeyaBegum
This document provides guidance on diagnosing and managing polycystic ovarian syndrome (PCOS) in adolescents. Key points include:
- Adult PCOS diagnostic criteria are not applicable to adolescents due to normal irregular periods and cystic ovaries during puberty.
- Recommended diagnostic approach involves assessing for unexplained hyperandrogenism and ovarian dysfunction after ruling out other conditions.
- Management involves lifestyle changes like weight loss, exercise and diet, as well as symptom-focused treatments like birth control pills, anti-androgens and insulin-sensitizing agents.
- The goals are to alleviate current symptoms, decrease future health risks of PCOS like infertility, metabolic syndrome and diabetes. Care must be taken to
COMPLICATIONS OF ASSISTED REPROUCTIVE TECHIQUESDrRokeyaBegum
Assisted reproductive techniques (ART) such as IVF and ICSI can help treat infertility but also carry several risks. A major complication is ovarian hyperstimulation syndrome (OHSS) which can range from mild to severe/critical. Prevention strategies include using the lowest effective drug doses, coasting, GnRH agonist triggering, and cryopreserving all embryos. Other risks include multiple pregnancies, preterm birth, and pregnancy complications. Careful patient selection and monitoring can help reduce risks from ART.
1. Polycystic ovary syndrome (PCOS) is a complex clinical syndrome with unclear etiology and various risk factors including genetics, environment, and obesity.
2. PCOS is characterized by menstrual irregularities, hirsutism, acne, infertility and obesity. It can cause insulin resistance, endometrial cancer risk, and other metabolic complications.
3. Diagnosis of PCOS involves requiring two of three criteria - oligo/amenorrhea, clinical or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound. Differential diagnoses must be excluded.
This document discusses trends in ovulation induction in patients with polycystic ovary syndrome (PCOS). It covers the hormonal mechanisms of normal ovulation and pathophysiology of PCOS. Treatment options discussed include lifestyle modification, oral ovulation induction drugs like clomiphene citrate and letrozole, insulin sensitizers, injectable gonadotropins, and ovarian drilling. The risks, benefits, and effectiveness of each approach is evaluated to determine the optimal individualized treatment strategy based on a patient's characteristics and treatment goals.
Postpartum haemorrhage (PPH) is commonly defined as a blood loss of 500 ml or more within 24 hours after birth.
It affects about 5% of all women giving birth around the world.
Globally, nearly one quarter of all maternal deaths are associated with PPH. In most low-income countries, it is the main cause of maternal mortality.
Pruritus affects upto 20% of pregnant women.
There are conditions unique to pregnancy that involve pruritus as a leading symptom.
This is called dermotoses of pregnancy.
May produce risk to mother and foetus.
Approach to skin lesions in pregnancy: Pruritus related to pregnancy, Pruritus not related to pregnancy
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
1. Endometriosis with low AMH.
How to deal with it
PROF. ROKEYA BEGUM
Advisor
Dept. of Obs and Gynecology USTC.
Director
Surgiscope fertility centre
Chittagong.
3. Endometriosis….
i) Defined as the presence of endometrial tissue (gland/stroma) outside the
uterus.
ii) Prevalence is 7-15% of reproductive age women .
iii) 70 million of women are affected with endometriosis 30% of these women
are infertile.
iv) Estrogen dependent
- Rare before menarche and after menopause.
- Not in male
v) Progressive disease
vi) Cure by pregnancy
4. Sites of Endometriosis…
i) Peritoneum
ii) Ovaries
iii) Rectovaginal septum
iv) Urinary bladder
v) GI Tract
5. Ovarian function…
i) Hormone production
ii) Maintenance of follicular development
iii) Reservoir of dormant oocyte.
6. Pathogenesis of ovarian endometriosis is still a matter of debate.
- Superficial ovarian endometriosis.
- Accumulation and activation of pelvic macrophage.
Local inflammatory response, fibrosis of cortical tissue damage of dormant primordial follicle
Progression of formation of endometriotic lesion in superficial ovarian cortex
Provoke invagination of ovarian superficial endometriosis facilitates cyst formation.
The cyst wall of endometriosis may show various degree of haemosiderin laden macrophages.
Cyst wall show dense fibrosis adjacent to normal ovarian time.
7. The multipotent stem cells which can form endometriotic
lesion and further progression of stem cell derived lesion via
tissue remodelling may be modulated by ovarian steriod
hormone and local inflammation.
Accumulation and trafficking of these stem cells can be
stimulated by oestradiol and immune cells.
Local immune cells such as in variant natural killer T (NKT)
cells may be involved in pathogenesis of endometriosis.
8. Ovarian steroid hormone production
The direct effects of endometriosis on ovarian steroid hormone production
are unclear.
Altered follicular development can result in decreased hormone production
lower level of oestrogen and progesterone have been noted in serum and
urine .
Impairment of ovulatory process causes LUFS. The causal relationship
between endometriosis and LUFS are unclear and controversial.
9. Oocyte quality…
Oocyte maturity can be affected by inflammatory intrafollicular
environment. The presence of intrafollicular oxidative stress in
patients with endometriosis is an event that is directly linked to
reduced oocyte quality and infertility.
Oxidative stress brought by hemorrhagic chocolate fluids in
endometriosis may spread to surrounding normal ovarian tissue.
Assessment of quality of follicle in clinical setting is not straight
forward.
10. Quantity…
Ovarian reserve is a term concerning the quality and quantity of
ovarian follicles remains at certain time points.
Ovarian reserve may refer to the quantity of remaining primordial
follicles are formed in the course of ovarian development in foetal life
than they maintain dormancy until they are activated in later
reproductive life.
11. Presence of ovarian endometriosis on ovarian
reserve-
1.Adjacent ovarian tissue is morphologically altered but not functionally.
2.Compression by cyst hamper circulation and causes follicular loss.
3. Inflammatory reaction causes follicular damage.
4. Impaired vascularization.
5.High concentration of iron in cyst mediates the production of reactive
oxygen species. Reactive oxygen species (ROS) along with transforming
growth factor is potent inducer of tissue fibrosis which causes follicular
loss. Reactive oxygen species (ROS) is responsible for progressive ovarian
tissue damage.
14. Assessment of ovarian reserve in endometriosis has to
be done by-
• Serum Antimullerian hormone (AMH)
• Serum Follicle stimulating hormone (FSH)
• Antral follicle count (AFC)
FSH and AFC have limitation-
• FSH – higher intercycle variation
• AFC – Not accurate with endometrioma.
15. Indeed in two large Cohot studies shown women
with history of endometriosis related infertility
are reported to experience menopause earlier
than women without endometriosis.
16. Endometriosis patients suffers from…
1. Pain
2. Infertility
3. Menstrual disturbances
4. Lump in lower abdomen
5. Quality of life
6. Negative influence on sexual function
7. Inter personal relationship.
17. Endometriosis is associated with infertility..
Fertility reduction is subjective choice and
women could be informed but absolutely must
not be terrorized leading to unnecessary stress
and intervention.
19. * Medical treatment :
- long term suppression
- Reduces pain
- Reduced growth of lesion
- Protect ovarian function
1. GnRh agonist
2. Dienogest
20. • Medical treatment suppresses general and
peripheral oestrogen production result in better
treatment outcome in ART cycle.
• Reduction of endometriosis activity may
restore endometrial receptivity as well as
maintenance of ovarian reserve.
21. 1. GnRh agonist -
a. Reduce cyst size
b. Reduction of hyper vascularization and inflammation.
c. Reduction of cyst wall thickness.
d. Absence of corpus luteum or follicle.
e. Facilitation of surgery
f. Reduction of adhesion
23. 2. Dienogest -
Acts on multiple receptors
a) Oestrogen
b) Androgen
c) Gluco corticoid
d) Mineralo corticoid
Dienogest has little impact on the metabolic parameter and
having a significant impact on endometriotic lesion locally.
24. Dienogest has -
a. anti inflammatory
b. Modulation of proinflammatory cytokine and chemokine
production-which mediates via progesterone receptor.
It is questionable whether dienogest can improve the clinical
outcome if use before IVF or surgery.
25. Surgery indicated in
i) large endometrioma > 4cm
ii) Extensive pelvic endometriosis
iii) Prior IVF
iv) Failure to hormone therapy
27. Aim of surgery
Reconstruction of normal pelvic anatomy to achieve an
excellent tubo-ovarian relationship and removed all visible disease .
Laparoscopy is preferred over laparotomy.
Ovarian tissue was present in cyst wall
- 65% laparoscopy stripping
- 80% laparotomy.
28. All ovarian cyst are not created equal
Ovarian tissue removed
Well defined Capsule
Dermoid 6%
Serious cyst adenoma
Mucinous cyst adenoma
Endometrioma
54-69%
(Margin of the ovarian tissue)
The structural difference among different ovarian cysts yield
different amounts of adjacent ovarian tissue when they are
removed.
29. Endometriosis is a false cyst and its cyst wall is
the same as the ovarian cortex.
Therefore unsafe removal of pseudo cyst may
damage the ovary and interfere with future
fertility.
30. Laparoscopy is Gold standard.
Ongoing pregnancy rate increased in infertile
women with endometriosis after laparoscopy.
Chance of pregnancy increased from 38-71%
cases.
31. Benefits of surgery…
a. Decreased inflammations in pelvis.
b. Decreased toxicity to gametes.
c. Enhance uterine receptivity.
32. High recurrence rate versus potential harmful effects on
ovarian reserve make it difficult to select the most
effective treatment modality for endometriosis.
• Incomplete excision – recurrence high
• Excessive excision – reduced reserve
34. Reduction of ovarian reserve due to-
a. Removal of healthy tissue during stripping.
b.Vascular injury to electrosurgical coagulation.
c. Inflammatory reaction.
35. Surgical technique for cystectomy-
1. Mobilisation of ovaries
2. During mobilisation cyst usually drain
on itself from the weakest point.
3. Cyst decompression by suction drainage.
4. Pitressin/vesopressin injection.
5. Cyst wall removed from normal ovarian tissue by traction and
counter traction.
6. Achieve complete haemostasis by suture not by bipolar current.
36. Three step techniques for ovarian endometrioma
1. Laparoscopic drainage
2. GnRh for 3 months
3. Laparoscopic Co2 laser vaporization.
37. The factors which determine the amount of loss of
follicles during surgery is dependent on many factors:
1. Use of electro cautery
2. Amount of inflammation
3. Number of pre existing follicle
4. Endometrioma is bilateral
5. Previous surgery
6. Expertise of surgery
38. Several cross section shows endometrioma had
lower ovarian reserve without surgery then
healthy women.
This decline is progressive in the absence
of any intervention and greater in
magnitude.
39. Ovarian reserve in endometriosis depends on-
a. Bilateral / unilateral disease.
b. Size of cyst
c. Severe adhesion
d. Fibrosis
e. Disease duration
f. Women’s age
g.Recurrence
41. Surgery ART
Age Young Old
Associated factor
- Male
- Tube
No Yes
Infertility duration Short Long
Ovarian reserve Satisfactory Reduced
Pelvic pain Severe Mild
Ovarian Endometrioma
bilateral
No Yes
Previous surgery No Yes
Adenomyomis No Yes
42. Anti mullerian hormone level in women with endometriosis.
A case-control study.
Object – To compare the Antimullarian hormone (AMH) level in
women with or without endometriosis.
Design – A case control study
Getting – Women’s general hospital, Lint, Austria.
Result – Mean AMH level was significantly lower in the study group
than in the control group (2.75 + 2.0mg/ml vs 3.46 + 2.30mg/ml P0.001)
OMAR SHEBL 2009.
43. Effect of ovarian endometrioma on the number of oocyte retrieved
for in vitro fertilization.
Objective – To evaluate the effects of ovarian endometrioma on the number of oocytes retrieved
for IVF.
Setting – University based tertiary medical center.
Patients – 81 women with unilateral endometrioma who under want first IVF cycle.
Main outcome measures –
The number of antral follicles and the retrieved oocyte in the ovary that contained endometrioma
were compared with those from contralaterd ovary results –Antral follicle count and number of
retrieved oocytes in these women were similar to those with no endometrionma.
Conclusion - The presence of ovarian endometrioma in a controlled ovarian hyper stimulation
cycle for IVF treatment is not associated with reduced number of oocytes retrieved from affected
ovary.
Benny Almog 2010
44. The impact of electrocoagulation on ovarian
reserve after laparoscopic excision of ovarian cyst .
Design-Prospective clinical study on 191 patients.
Objective- Bipolar, Ultrasonic scalpel and Suture.
Result- Significant reduction in ovarian reserve in bipolar.
Chang Zhong Li- 2009
45. Endometriosis patient should be assessed
individually and follow seven guidelines in order
to preserve fertility.
46. 1. Choosing the best surgical techniques.
Still not known which one is most effective.
Surgery can lead to reduction in ovarian reserve
i) Excessive stripping
ii) Disease itself
iii) Cauterization to stop bleeding
iv) Surgery induce inflammation
v) Cystectomy
vi) Bilateral
vii) Large endometriona
48. 3. Measure ovarian reserve before surgery.
a) Discussion of risks and benefits of surgery.
b) Allowing the surgery to optimize and individual treatment
modalities.
c) Aggressive nature of surgery should be avoided.
d) Fertility preservation should be offered.
49. 4. Emergency IVF before surgery
1. Older patient > 38yrs
2. Prolong infertility
3. Low AMH
50. 5. Use of GnRh analogues
i) Hypoestrogenic state
ii) Increase natural killer cell activity and diminished
embryotoxic effects of peritoneal fluid
iii) Ovarian parenchyma damage during the surgery seems to
be related to cyst diameter.
GnRh analogue is useful for both before surgery and IVF.
53. Ovarian cortical tissue cryopreservation
- Re implantation of cortical ovarian tissue into the pelvic cavity or
heterotopic site.
- When patient become disease free, the implanted tissue can be used
in IVF and ET procedure.
This method is associated with 25% follicle survival and is most successful
when patient is young.
Ovarian tissue cryopreservation
is still experimental although
pregnancies have been reported.
54. 7.Role of lifestyle changes in infertile patient with endometriosis-
i) Avoid late childhood obesity
ii) Avoid high trans fat
iii) Avoid caffeine
iv) Avoid alcohol
55. ART is a hope of ray for
Infertile patient with low AMH.
Conclusion